Back to OCULOcular Therapeutix, Inc. (OCUL)View full pipeline
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
Phase 300%
What is LOA?Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Mar '27
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 Phase 3 Est. Readout (HELIOS-3)
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24930
Competitive Landscape
0 competitors in Non-Proliferative Diabetic Retinopathy
View Full LandscapeDrug Information
Target Indication
Non-Proliferative Diabetic Retinopathy
Clinical Trial
NCT07235085Last updated: 10/21/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Ophthalmic InsertPhase 3
Open Angle Glaucoma and Ocular Hypertension
Punctum PlugPhase 3
Post Ocular Surgical Inflammation and Pain
OTX-TKI (axitinib implant)Phase 3
Neovascular Age-Related Macular Degeneration
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Phase 3
Non-Proliferative Diabetic Retinopathy
Dextenza Ophthalmic InsertPhase 3
Cataract
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts